



DeLong's test for two correlated ROC curves

Z=-0.05, p=0.961

Model: Three-months clinical response – $KIR2DL2/DL3+NKs$ after 1 month

Optimal Cut-off value: 23.3

AUC: 0.677(0.523-0.832), p<0.001

Model: Three-months clinical response – $CD3^+$ after 1 month

Optimal Cut-off value: 71

AUC: 0.672(0.529-0.815), p<0.001

Supplementary Figure S10. .632+ cross validation bootstrap ROC curves and the optimum T1 cut-off values of $CD3^+$ and $KIR2DL2/DL3+NKs$ to determine the outcome of REV patients. The blue curve represents the ROC curve derived by selected cut-off point of 71 on the $CD3^+$ level after one month of nivolumab treatment, with AUC estimated by .632+ cross validation equal to 0.672 (95%CI: 0.529-0.815) and p<0.001. Red curve represents the ROC curve derived by selected cut-off point of 23.3 on the $KIR2DL2/DL3+NKs$ level after one month of nivolumab treatment, with AUC estimated by .632+ cross validation equal to 0.677 (95%CI: 0.523-0.832) and p<0.001. Additionally, a DeLong's test statistics of the difference between ROC curves was performed with a not statistically significant result (p=0.961).